Cancer

TUESDAY, MAY 23, 8:00AM-7:00PM

Allergy	Hematological Disorders	Patient-Reported Outcomes
Asthma	Infection	Skin
Cancer	Muscular-Skeletal Disorders	Smoking
Cardiovascular Disease	Osteoporosis	Surgery
Ear	Other	Health Care Use & Policy
Eye	Pain


Cancer

PCN1	ESTIMATING THE EFFECTIVENESS OF EARLY-STAGE LUNG CANCER ADJUVANT TREATMENTS IN PRACTICE USING INSTRUMENTAL VARIABLE METHODS Brooks JM1, Chrischilles EA2, Chen-Hardee S1, Cho E1, Scott SD3 1University of Iowa, Iowa City, IA, USA, 2Univerisity of Iowa, Iowa City, IA, USA, 3University of Newcastle, Newcastle, Australia
PCN2	Withdrawn

PCN3	AN ANALYSIS OF OUTPATIENT SERVICE UTILIZATION FOR DELAYED NAUSEA AND VOMITING USING ELECTRONIC MEDICAL RECORDS Forsyth M1, Conner T1, Curtis V1, Johnsrud M2 1US Oncology, Houston, TX, USA, 2University of Texas at Austin, Austin, TX, USA

PCN4	RETROSPECTIVE COHORT STUDY OF TAMOXIFEN TREATED BREAST CANCER PATIENTS ASSOCIATED WITH RISK OF ENDOMETRIAL CANCER Wang C, He J, Griffin B, Mahoney A, Burleigh E Solucient, Berkerley Heights, NJ, USA

PCN5	QUALITY IN HEALTH CARE SERVICES FOR WOMEN WITH BREAST CANCER AND ITS ECONOMIC CONSEQUENCES IN MEXICO Contreras-Hernandez I1, Mould J1, Pico-Guzman J2, Ayala-Hernandez JR1, Garduño-Espinosa J1 1Social Security Mexican Institute, Mexico City, Mexico, 2Life Sciences Consulting, Madrid, Spain

PCN6	HOSPITAL INPATIENT UTILIZATION OF EPOETIN ALFA (EPO) AND DARBEPOETIN ALFA (DARB) IN PATIENTS WITH CANCER AND PRE-DIALYSIS CHRONIC KIDNEY DISEASE (PCKD) Smith J1, He J1, Mahoney A1, Noone P2, Watson S3, Mody S3, Mckenzie RS3 1Solucient, LLC, Berkeley Heights, NJ, USA, 2Ortho Biotech Products, LP, Bridgewater, NJ, USA, 3Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA

PCN7	WITHDRAWN

PCN8	COST-EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY WITH URACIL-TEGAFUR, AN ORAL FLUOROPYRIMIDINE DERIVATIVE, IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER IN JAPAN Ikeda S1, Sakamaki H2, Yajima S2, Ikegami N2 1International University of Health and Welfare, Otawara-shi, Tochigi, Japan, 2Keio University, Shinjuku-ku, Tokyo, Japan

PCN9	ECONOMIC EVALUATION OF ANTIEMETIC REGIMENS FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING Mody RR1, Miller LA2, Higa G2, Scott V2, Madhavan SS2, Abraham J2 1TAP Pharmaceutical Products Inc, Lake Forest, IL, USA, 2West Virginia University, Morgantown, WV, USA

PCN10	COST-EFFECTIVENESS OF GEMCITABINE-PACLITAXEL COMBINATION IN THE TREATMENT OF ADVANCED BREAST CANCER AFTER FAILURE OF ANTHRACYCLINE THERAPY Davey P1, Arora BK2, Le Reun C1, Rajan N2, Liepa AM3, Pavlakis N4 1M-TAG Pty Ltd - A unit of IMS Health, Sydney, NSW, Australia, 2Eli Lilly Australia Pty, Ltd, West Ryde, NSW, Australia, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Royal North Shore Hospital, St. Leonards, NSW, Australia

PCN11	COST EFFECTIVENESS OF ADJUVANT, INTRAVESICAL THERAPY FOR NON-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER Kerrigan M1, Ramsey S2, Penson D3, Blough DK1, Garrison L1 1University of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 3University of Southern California / Norris Cancer Center, Los Angeles, CA, USA

PCN12	COST-EFFECTIVENESS ANALYSIS OF G-CSF IN ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKIN'S LYMPHOMA (NHL) RECEIVING CHOP Lyman GH1, Cosler LE2 1University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, 2Albany College of Pharmacy, Albany, NY, USA

PCN13	COST-EFFECTIVENESS ANALYSIS OF APREPITANT IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PATIENTS RECEIVING EITHER CISPLATIN-BASED CHEMOTHERAPY REGIMENS OR MODERATELY EMETOGENIC CHEMOTHERAPY Annemans L1, Strens D1, Lox E2, Petit C2, Malonne H2 1HEDM-IMS Health, Brussels, Belgium, 2Merck Sharp & Dohme bv, Brussels, Belgium

PCN14	COST - EFFECTIVENESS OF TAXANES AS SECOND LINE AGENTS IN TREATMENT OF METASTATIC BREAST CANCER Kawatkar AA, Hay JW University of Southern California, Los Angeles, CA, USA

PCN15	THE ANNUAL HEALTH INSURANCE COST OF COLORECTAL CANCER TREATMENT IN HUNGARY: A COST OF ILLNESS STUDY Boncz I1, Sebestyén A1, Palásti J1, Betlehem J2 1National Health Insurance Fund Administration (OEP), Budapest, Hungary, 2University of Pécs, Pécs, Hungary

PCN16	ECONOMIC OUTCOMES IN HEPATOCELLULAR CARCINOMA AND METASTATIC LIVER DISEASE PATIENTS: A MEDICARE PERSPECTIVE Pelletier EM1, Dembek CJ1, Gazelle GS2 1Boston Scientific Corporation, Natick, MA, USA, 2Massachusetts General Hospital, Boston, MA, USA

PCN17	EVALUATING THE COST OF CARE FOR EARLY AND LATE STAGE OROPHARYNGEAL CANCER IN THE CALIFORNIA MEDICAID POPULATION Epstein JD1, Knight TK1, Epstein JB2, Bride M3, Nichol MB1 1University of Southern California, Los Angeles, CA, USA, 2University of Illinois at Chicago, Chicago, IL, USA, 3Zila, Inc, Phoenix, AZ, USA

PCN18	CLINICAL AND ECONOMIC OUTCOMES OF INITIAL ACUTE MYELOBLASTIC LEUKEMIA (AML) HOSPITALIZATION IN THE ELDERLY Nuyts G1, Janagap C1, Zilberberg M2, Piech CT2 1Johnson and Johnson, Raritan, NJ, USA, 2Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA

PCN19	COLONOSCOPY AND FLEXIBLE SIGMOIDOSCOPY: A MICROCOSTING STUDY EVALUATING DIAGNOSTIC PROCEDURAL COSTS IN AN OUTPATIENT ENDOSCOPY CLINIC Sambrook JC1, Chui W1, Wang H1, Levy AR1, Enns RA2 1Oxford Outcomes Ltd, Vancouver, BC, Canada, 2St. Paul's Hospital, Vancouver, BC, Canada

PCN20	COSTS OF THE DIFFERENT TREATMENTS FOR PATIENTS WITH BREAST CANCER IN THE MEXICAN INSTITUTE OF SOCIAL SECURITY (IMSS). Salinas-Escudero G1, Mould J1, Duran-Arenas L1, Martinez-Valverde S2, Garduño-Espinosa J1 1Social Security Mexican Institute, Mexico City, Mexico, 2Social Security Research Unit, Mexico City, Mexico

PCN21	4D LOCALIZATION SYSTEM WITH TRANSPONDERS FOR CONTINUOUS TARGET LOCALIZATION FOR SET-UP AND TRACKING DURING RADIATION THERAPY: EARLY HEALTH TECHNOLOGY ASSESSMENT Williams E1, Papatheofanis FJ2 1AEQUITAS, San Diego, CA, USA, 2UCSD, San Diego, CA, USA

PCN22	THE EFFECT OF EFFICIENCY OF ACCESS TO CARE Younis M1 1Tulane, New Orleans, LA, USA
PCN23	THE EFFECT OF ORGANIZED MAMMOGRAPHY SCREENING ON THE NUMBER OF BREAST SURGERIES Boncz I1, Sebestyén A2, Budai A3, Ember I4 1National Health Insurance Fund Administration (OEP), Budapest, Hungary, 2National Health Insurance Fund Administration (OEP), Pécs, Hungary, 3National Public Health and Medical Officers Service (ÁNTSZ), Budapest, Hungary, 4University of Pécs, Pécs, Hungary

PCN24	DEFINING GUIDELINES ON BRCA MUTATION TESTING AT A MEDICAL ONCOLOGY UNIT- AT AN UNIVERSITY HOSPITAL IN SOUTH-EASTERN BRAZIL Brentani A1, Diz MDPE2, Maistro S1 Snitcovsky I2, Federico M1 1Faculdade de Medicina da universidade de Sao Paulo, Sao Paulo, Brazil, 2Hospital das Clínicas da FMUSP, São Paulo, Brazil, 3Faculdade de Medicina Da Universidade de São Paulo, Sao Pulo, Brazil

PCN25	REAL WORLD DOSING OF ERYTHROPOIETIC AGENTS IN A NATIONWIDE SAMPLE OF PATIENTS WITH CANCER RECEIVING CHEMOTHERAPY: RESULTS FROM A LARGE RETROSPECTIVE OBSERVATIONAL STUDY McLaughlin T1, Mody S2, Mckenzie RS2 1Stanford University Medical Center, Stanford, CA, USA, 2Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA

PCN26	INTER-RATER AGREEMENT OF HUI3 UTILITY SCORES FOR PATIENTS AT FOUR PHASES OF THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD: PARENT VERSUS CLINICIAN ASSESSMENT Rae CS1, Furlong W1, Gelber R2, Barr RD1 1McMaster University, Hamilton, ON, Canada, 2Harvard University, Boston, MA, USA

PCN27	HEALTH STATUS MEASURES AS PREDICTORS OF MORTALITY AMONG ADULTS WITH BRAIN TUMORS Furlong W1, McCarter H2, Whitton AC2, Feeny D3, DePauw S1, Willan AR4, Barr RD1 1McMaster University, Hamilton, ON, Canada, 2Juravinski Cancer Centre, Hamilton, ON, Canada, 3Institute of Health Economics, Edmonton, AB, Canada, 4Hospital for Sick Children, Toronto, ON, Canada

PCN28	REVIEW OF ECONOMIC APPRAISALS OF CHEMOTHERAPY FOR METASTATIC COLORECTAL CANCER Hornberger J1, Robertus K1, Bhattacharyya SK2, Deeter R2 1Acumen, LLC, Burlingame, CA, USA, 2Amgen Inc, Thousand Oaks, CA, USA

PCN29	GAPS IN THE ECONOMIC EVALUATION OF PROSTATE CANCER Komatsuzaki Y1, Atzinger C1, Lee WC2, Pashos CL2 1Abt Associates Inc, Bethesda, MD, USA, 2Abt Associates Inc, Lexington, MA, USA

PCN30	WITHDRAWN

PCN31	A METHOD TO REMOVE CONTINUOUS ENROLLMENT REQUIREMENT FROM PHARMAECONOMIC STUDIES Baser O Thomson-Medstat, Ann Arbor, MI, USA

PCN32	MODELING AND ESTIMATING PREFERENCES OVER TREATMENTS FOR BREAST CANCER: APPLIED CONJOINT ANALYSIS WITH PHYSICIANS IN EUROPE AND UNITED STATES Walzer S1, Memran M2, Morlotti L1 1Analytica International, Loerrach, Germany, 2Analytica International, New York, NY, USA
PCN33	MAPPING FACT-P AND EORTC QLQ-C30 TO THE EQ-5D HEALTH UTILITY IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER PATIENTS Wu E1, Mulani P2, Farrell MH1, Sleep D2 1Analysis Group, Inc, Boston, MA, USA, 2Abbott Laboratories, Abbott Park, IL, USA

PCN34	VALIDATION OF AN INTERNET-BASED PATIENT HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE: DATA FROM CAPSURE Broering JM1, Lessard SC1, Marr PL1, Elkin EP1, Lewis KR2, Olesek G2, Carroll PR1, DuChane J3 1University of California, San Francisco, San Francisco, CA, USA, 2Secure Outcomes Corporation, Santa Clara, CA, USA, 3TAP Pharmaceutical Products, Inc, Lake Forest, IL, USA

PCN35	DEVELOPMENT AND VALIDATION OF A DISEASE-SPECIFIC, NEUROENDOCRINE TUMOR QUESTIONNAIRE (QOL-NET), TO MEASURE PATIENTS' PERCEPTION OF THE EFFECTS OF DISEASE ON THEIR QUALITY OF LIFE (QOL) Vinik EJ, Ford-Molvik SL, Vinik AI Eastern Virginia Medical School, Norfolk, VA, USA

PCN36	DEVELOPING HEALTH STATE DESCRIPTIONS FOR METASTATIC COLORECTAL CANCER: QUALITATIVE STUDY Lloyd A1, van Hanswijck de Jonge P1, Doyle S1, Walker M2, Cohen C2 1United Biosource Corporation, London, UK, 2Roche Products Ltd, Welwyn Garden City, Herts, UK

PCN37	ESTIMATION OF A SET OF PATIENT-BASED UTILITY WEIGHTS FOR THE FACT-G Dobrez D1, Pickard AS2, Cella D3, Lai JS4, Nickolov A5 1University of Illinois at Chicago, Chicago, IL, USA, 2College of Pharmacy, UIC, Chicago, IL, USA, 3Evanston Northwestern Healthcare, Chicago, IL, USA, 4Evanston Northwestern Healthcare, Evanston, IL, USA, 5Mallinckrodt/Tyco Healthcare, St Louis, MO, USA

PCN38	PROPENSITY SCORE MATCHING WITH LIMITED OVERLAP Baser O Thomson Medstat, Ann Arbor, MI, USA

PCN39	A SYSTEMATIC REVIEW OF THE UCLA PROSTATE CANCER INDEX'S MEASUREMENT PROPERTIES Epstein JD1, Gwadry-Sridhar F2 1University of Southern California, Los Angeles, CA, USA, 2University of Western Ontario, and London Health Sciences Centre, London, ON, Canada

PCN40	THE IMPACT OF HUMAN PAPILLOMAVIRUS INFECTION AND CERVICAL CANCER ON HEALTH-RELATED QUALITY OF LIFE: A REVIEW OF VALIDATED INSTRUMENTS CURRENTLY AVAILABLE Rofail D1, Abetz L2, Jenkins D3, Lindsay L3, De Vuyst H3 1Mapi Values Limited, Macclesfield, Cheshire, UK, 2Mapi Values Limited, Bollington, Cheshire, UK, 3GSK Biologicals, Rixensart, Belgium

PCN41	EQ-5D IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ASSESSMENT OF VALIDITY AND RESPONSIVENESS. Sundaram M1, Kutikova L2, Enas NH2, Lu H2, Liepa AM2 1West Virginia University School of Pharmacy, Morgantown, WV, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

PCN42	PREDICTIVE VALUE OF SERIAL MEASUREMENTS OF QUALITY OF LIFE ON ALL-CAUSE MORTALITY IN PROSTATE CANCER PATIENTS: DATA FROM CAPSURETM Sadetsky N1, Elkin EP2, Carroll PR2 1UCSF, San Francisco, CA, USA, 2University of California, San Francisco, San Francisco, CA, USA

PCN43	A SYSTEMATIC REVIEW OF THE EORTC QLQ-BR23: DESCRIPTIVE HEALTH RELATED QUALITY OF LIFE INSTRUMENT USED IN BREAST CANCER Kawatkar AA1, Gwadry-Sridhar F2 1University of Southern California, Los Angeles, CA, USA, 2University of Western Ontario, and London Health Sciences Centre, London, ON, Canada

PCN44	IMPROVEMENT IN SENSORY PAIN RATING AFTER PALLIATIVE RADIONUCLIDE THERAPY IN PATIENTS WITH ADVANCED PROSTATE CANCER Papatheofanis FJ1, Marangos P2 1UCSD, San Diego, CA, USA, 2Aequitas, San Diego, CA, USA

PCN45	EFFECT OF AGE ON PREFERENCES FOR HEALTH OUTCOMES IN PROSTATE CANCER Krahn MD1, Bremner K1, Tomlinson G2, Alibhai S3, Laporte A4, Naglie G5 1University Health Network, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Unviersity Health Network, Toronto, ON, Canada, 4Department of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, 5Unversity Health Network, Toronto, ON, Canada

PCN46	ONLINE REPORTING OF TOXICITY SYMPTOMS BY LUNG CANCER PATIENTS DURING CHEMOTHERAPY Basch E, Barz A, Kris M, Culkin A, Schrag D Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Contributed Posters Session I